Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoni

Abstract

BackgroundThe near exclusive use of praziquantel (PZQ) for treatment of human schistosomiasis has raised concerns about the possible emergence of drug-resistant schistosomes.Methodology/Principal FindingsWe measured susceptibility to PZQ of isolates of Schistosoma mansoni obtained from patients from Kisumu, Kenya continuously exposed to infection as a consequence of their occupations as car washers or sand harvesters. We used a) an in vitro assay with miracidia, b) an in vivo assay targeting adult worms in mice and c) an in vitro assay targeting adult schistosomes perfused from mice. In the miracidia assay, in which miracidia from human patients were exposed to PZQ in vitro, reduced susceptibility was associated with previous treatment of the patient with PZQ. One isolate (“KCW”) that was less susceptible to PZQ and had been derived from a patient who had never fully cured despite multiple treatments was studied further. In an in vivo assay of adult worms, the KCW isolate was significantly less susceptible to PZQ than two other isolates from natural infections in Kenya and two lab-reared strains of S. mansoni. The in vitro adult assay, based on measuring length changes of adults following exposure to and recovery from PZQ, confirmed that the KCW isolate was less susceptible to PZQ than the other isolates tested. A sub-isolate of KCW maintained separately and tested after three years was susceptible to PZQ, indicative that the trait of reduced sensitivity could be lost if selection was not maintained.Conclusions/SignificanceIsolates of S. mansoni from some patients in Kisumu have lower susceptibility to PZQ, including one from a patient who was never fully cured after repeated rounds of treatment administered over several years. As use of PZQ continues, continued selection for worms with diminished susceptibility is possible, and the probability of emergence of resistance will increase as large reservoirs of untreated worms diminish. The potential for rapid emergence of resistance should be an important consideration of treatment programs.

Infection with Opisthorchis viverrini and Use of Praziquantel among a Working-age Population in Northeast Thailand

“…Secondly, a continued extensive use of praziquantel may eventually result in drug resistance, just as has happened with so many antibiotics and antimalarial drugs. In vivo and in vitro tests have shown that praziquantel resistance can develop in another potentially life-threatening trematode, Schistosoma mansoni (Melman et al, 2009). Thirdly, it is not known how many people given praziquantel for OV infection actually take it as recommended.…”

The Potential Ameliorative Effect of Curcumin in Schistosoma Mansoni Infected Mice: An Ultrstructural Study on the Testes

“…H owev er, the drug does not treat earl y i nf ecti on or prevent reinfec tion (Mag nuss en, 2003) and numer ous evide nc es indicated i ncreasing t he em ergenc e of S . mans oni strai ns r esist ant t o PZQ ( Melman et al, 2009;Z hang and C oultas , 2013). Ther ef ore, dev elopment of new antiSchis tos oma drugs is pursued until deliver y of an eff ectiv e anti -Sc hist os oma v accine.…”

Metal Complexes and Medicine: A Successful Combination

“…Reduced susceptibility to PZQ has been reported, suggesting that this drug could become (much less) effective in the future. [17][18][19] This fact is extremely worrying since there is no current alternative to PZQ. In fact, since PZQ was marketed in 1984, no new drug has entered the market to fight this disease, [20] while the number of chemotherapeutic treatments against this disease gradually increased from 12.4 million people in 2006 to over 42.1 million people treated in 2012.…”